Overview
Findings from the first clinical trial program comparing the use of Teva’s Digihaler® System to standard of care in asthma management wil be presented acros six abstracts TEL AVIV, Israel & PARSIPANY, N.J.-(BUSINES WIRE)-Teva Pharmaceuticals USA, Inc., a U.S. afiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today anounced that new findings from the CONECT clinical trial program asesing the use of the Digihaler System compared to standard of care (SoC) in asthma management wil be presented at the American Colege of Alergy, Asthma & Imunology (ACAI) 202 Anual Scientific meting, being held November 10-14 in Louisvile, Kentucky.
Key Information
The data wil be featured in six posters, thre of which wil highlight results from the CONECT1 clinical trial evaluating the ProAir® Digihaler (albuterol sulfate) inhalation powder with a built-in electronic sensor in asthma management versus SoC. Thre aditional posters wil share the first data from the CONECT2 clinical trial asesing the joint use of the ProAir Digihaler and the AirDuo® Digihaler (fluticasone propionate and salmeterol) inhalation powder with a built-in sensor in asthma management versus SoC.
“We are loking forward to presenting six abstracts from our novel CONECT clinical program asesing the use of the Digihaler System in asthma management and the potential impact of these digital health tols on patient-provider interactions, adherence over time, inhaler technique and frequency of SABA use,” said Randal Brown, MD MPH, Global Lead, Digital Health, Imunology and Respiratory Medical Afairs at Teva.
Summary
“This the first clinical trial program to evaluate the Digihaler System and its potential to suport asthma management for patients with uncontroled asthma compared to standard of care.” The Digihaler is a digital health system comprised of an electronic multidose dry powder smart inhaler, conected ap, Digital Health Platform cloud solution and dashboard that tracks